Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Review

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

Authors: Ester Fonsatti, Michele Maio

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed.
Literature
1.
Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003, 22: 7359-7368. 10.1038/sj.onc.1206939.CrossRefPubMed
2.
Ménard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003, 22: 6570-6578. 10.1038/sj.onc.1206779.CrossRefPubMed
3.
Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solid tumors. Cancer Treat Rev. 2000, 26: 269-286. 10.1053/ctrv.2000.0176.CrossRefPubMed
4.
Brekken RA, Li C, Kumar S: Strategies for vascular targeting in tumors. Int J Cancer. 2002, 100: 123-130. 10.1002/ijc.10462.CrossRefPubMed
5.
6.
Haruta Y, Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A. 1986, 83: 7898-7902.PubMedCentralCrossRefPubMed
7.
Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol. 1988, 141: 1925-1933.PubMed
8.
Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem. 1990, 265: 8361-8364.PubMed
9.
Bellón T, Corbi A, Lastres P, Calés C, Cebrian M, Vera S, Cheifetz S, Massagué J, Letarte M, Bernabéu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol. 1993, 23: 2340-2345.CrossRefPubMed
10.
Lastres P, Martín-Perez J, Langa C, Bernabéu C: Phosphorylation of the human-transforming-growth-factor-β-binding protein endoglin. Biochem J. 1994, 301: 765-768.PubMedCentralCrossRefPubMed
11.
Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995, 1: 1623-1634.PubMed
12.
Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Müller R, Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999, 81: 568-572. 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O.CrossRefPubMed
13.
Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M: Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res. 2000, 6: 2037-2043.PubMed
14.
Graulich W, Nettelbeck DM, Fischer D, Kissel T, Muller R: Cell type specificity of the human endoglin promoter. Gene. 1999, 227: 55-62. 10.1016/S0378-1119(98)00585-X.CrossRefPubMed
15.
Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C: Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002, 100: 4001-4010. 10.1182/blood.V100.12.4001.CrossRefPubMed
16.
Wong SH, Hamel L, Chevalier S, Philip A: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 2000, 267: 5550-5560. 10.1046/j.1432-1327.2000.01621.x.CrossRefPubMed
17.
Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer. 1993, 54: 363-370.CrossRefPubMed
18.
Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM: Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994, 25: 1794-1798.CrossRefPubMed
19.
Schimming R, Marme D: Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck. 2002, 24: 151-156. 10.1002/hed.10040.abs.CrossRefPubMed
20.
Torsney E, Charlton R, Parums D, Collis M, Arthur HM: Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002, 51: 464-470.CrossRefPubMed
21.
Chung YC, Hou YC, Pan AC: Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest. 2004, 34: 107-112. 10.1111/j.1365-2362.2004.01305.x.CrossRefPubMed
22.
Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M: Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001, 188: 1-7. 10.1002/jcp.1095.CrossRefPubMed
23.
Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003, 22: 6557-6563. 10.1038/sj.onc.1206813.CrossRefPubMed
24.
Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L: Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst. 1994, 86: 386-388.CrossRefPubMed
25.
Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin [CD105] is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002, 51: 268-275. 10.1002/pros.10083.CrossRefPubMed
26.
Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M, Kumar S: Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol. 2003, 9: 2866-2869.CrossRefPubMed
27.
Cheifetz S, Bellón T, Calés C, Vera S, Bernabéu C, Massagué J, Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem. 1992, 267: 19027-19030.PubMed
28.
Lastres P, Letamendía A, Zhang H, Ríus C, Almendro N, Raab U, López LA, Langa C, Fabra A, Letarte M, Bernabéu C: Endoglin modulates cellular response to TGF-β1. J Cell Biol. 1996, 133: 1109-1121. 10.1083/jcb.133.5.1109.CrossRefPubMed
29.
Barbara NP, Wrana JL, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem. 1999, 274: 584-594. 10.1074/jbc.274.2.584.CrossRefPubMed
30.
Govinden R, Bhoola KD: Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther. 2003, 98: 257-265. 10.1016/S0163-7258(03)00035-4.CrossRefPubMed
31.
Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabéu C: Role of endoglin in cellular responses to transforming growth factor-β. J Biol Chem. 1998, 273: 33011-33019. 10.1074/jbc.273.49.33011.CrossRefPubMed
32.
Li C, Hampson IN, Hampson L, Kumar P, Bernabéu C, Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J. 2000, 14: 55-64.PubMed
33.
Ma X, Labinaz M, Goldstein J, Millere H, Keon WJ, Letarte M, O'Brien E: Endoglin is overexpressed after arterial injury and is required for transforming growth factor-β-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2000, 20: 2546-2552.CrossRefPubMed
34.
Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, Lopez-Novoa JM, Lamas S, Bernabeu C: Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta. 2002, 1587: 36-44. 10.1016/S0925-4439(02)00051-0.CrossRefPubMed
35.
Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem. 2002, 277: 29197-29209. 10.1074/jbc.M111991200.CrossRefPubMed
36.
Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003, 116: 2677-2685. 10.1242/jcs.00470.CrossRefPubMed
37.
Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA, Fabra A, Garcia-Pardo A, Vera S, Letarte M, Bernabeu C: Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol. 1999, 78: 614-623.CrossRefPubMed
38.
Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C, Roughley PJ, Bernabeu C: Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol. 2004, 22: 561-572. 10.1016/j.matbio.2003.11.006.CrossRefPubMed
39.
Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002, 277: 43799-43808. 10.1074/jbc.M207160200.CrossRefPubMed
40.
Ríus C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CPH, Bernabéu C: Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood. 1998, 92: 4677-4690.PubMed
41.
Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003, 34: 2483-8. 10.1161/01.STR.0000088644.60368.ED.CrossRefPubMed
42.
Li C, Guo B, Ding S, Rius C, Langa C, Kumar P, Bernabeu C, Kumar S: TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res. 2003, 23: 1189-1196.PubMed
43.
Ota TM, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K: Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol. 2002, 193: 299-318. 10.1002/jcp.10170.CrossRefPubMed
44.
Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res. 2002, 62: 7124-7129.PubMed
45.
Duff SE, Li C, Garland JM, Kumar S: CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003, 17: 984-992. 10.1096/fj.02-0634rev.CrossRefPubMed
46.
Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP: Defective angiogenesis in mice lacking endoglin. Science. 1999, 284: 1534-1537. 10.1126/science.284.5419.1534.CrossRefPubMed
47.
Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development. 1995, 121: 1845-54.PubMed
48.
Urness LD, Sorensen LK, Li DY: Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 2000, 26: 328-331. 10.1038/81634.CrossRefPubMed
49.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994, 8: 345-351.CrossRefPubMed
50.
Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M: Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol. 2001, 158: 2011-2020.PubMedCentralCrossRefPubMed
51.
van den Driesche S, Mummery CL, Westermann CJ: Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003, 58: 20-31. 10.1016/S0008-6363(02)00852-0.CrossRefPubMed
52.
Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C, Lopez-Novoa JM: Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 2004, 18: 609-611.PubMed
53.
Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, Abe T: Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery. 2002, 131 (1 Suppl): S109-113. 10.1067/msy.2002.119361.CrossRefPubMed
54.
Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004, 35: 176-183. 10.1016/j.humpath.2003.10.008.CrossRefPubMed
55.
Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Prediction of metastasis risk [11 year follow-up] using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer [n = 905]. Br J Cancer. 2004, 90: 1216-1221. 10.1038/sj.bjc.6601452.PubMedCentralCrossRefPubMed
56.
Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Ishikawa S, Wada H: Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer. 2003, 39: 289-296. 10.1016/S0169-5002(02)00534-2.CrossRefPubMed
57.
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407: 249-257. 10.1038/35025220.CrossRefPubMed
58.
Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 [TNP-470] and the anti-endoglin antibody TEC-11. Anticancer Drugs. 1997, 8: 238-244.CrossRefPubMed
59.
She X, Matsuno F, Harada N, Tsai H, Seon BK: Synergy between anti-endoglin [CD105] monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 2004, 108: 251-257. 10.1002/ijc.11551.CrossRefPubMed
60.
Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R, Kontermann RE: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin [CD105]. Mol Ther. 2001, 3: 882-891. 10.1006/mthe.2001.0342.CrossRefPubMed
61.
Velasco B, Ramirez JR, Relloso M, Li C, Kumar S, Lopez-Bote JP, Perez-Barriocanal F, Lopez-Novoa JM, Cowan PJ, d'Apice AJ, Bernabeu C: Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther. 2001, 8: 897-904. 10.1038/sj.gt.3301468.CrossRefPubMed
62.
Cowan PJ, Shinkel TA, Fisicaro N, Godwin JW, Bernabeu C, Almendro N, Rius C, Lonie AJ, Nottle MB, Wigley PL, Paizis K, Pearse MJ, d'Apice AJ: Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation. 2003, 10: 223-231.CrossRefPubMed
63.
Korn T, Muller R, Kontermann RE: Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother. 2004, 27: 99-106. 10.1097/00002371-200403000-00003.CrossRefPubMed
64.
Savontaus MJ, Sauter BV, Huang TG, Woo SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 2002, 9: 972-979. 10.1038/sj.gt.3301747.CrossRefPubMed
65.
Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R: Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer. 2000, 36: 675-681. 10.1016/S0959-8049(99)00335-4.CrossRefPubMed
66.
Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, Owens S, Al-Mowallad AF, O'Dwyer S, Kumar S: Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer. 2004, 109: 436-441. 10.1002/ijc.11699.CrossRefPubMed
67.
Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 1997, 3: 1031-1044.PubMed
68.
Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res. 1999, 5: 371-382.PubMed
69.
Tabata M, Kondo M, Haruta Y, Seon BK: Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer. 1999, 82: 737-742. 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#.CrossRefPubMed
70.
Takahashi N, Haba A, Matsuno F, Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin [CD105] monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001, 61: 7846-7854.PubMed
71.
Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat. 1996, 39: 239-242.CrossRefPubMed
72.
Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A: Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer. 2001, 94: 579-585. 10.1002/ijc.1505.CrossRefPubMed
73.
Seon BK: Expression of endoglin [CD105] in tumor blood vessels. Int J Cancer. 2002, 99: 310-311. 10.1002/ijc.10378.CrossRefPubMed
74.
Grisanti S, Canbek S, Kaiserling E, Adam A, Lafaut B, Gelisken F, Szurman P, Henke-Fahle S, Oficjalska-Mlynczak J, Bartz-Schmidt KU: Expression of endoglin in choroidal neovascularization. Exp Eye Res. 2004, 78: 207-213. 10.1016/j.exer.2003.11.008.CrossRefPubMed
75.
Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999, 59: 856-861.PubMed
76.
Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, Lavaut MN, Allasia C, Charpin C: CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol. 2003, 119: 374-380.CrossRefPubMed
77.
Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME: Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol. 2000, 96: 224-228. 10.1016/S0029-7844(00)00864-4.CrossRefPubMed
78.
Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003, 88: 1424-1431. 10.1038/sj.bjc.6600874.PubMedCentralCrossRefPubMed
79.
Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF: Endoglin [CD105] and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004, 17: 197-203. 10.1038/modpathol.3800034.CrossRefPubMed
80.
Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA: Significance of CD105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS. 2003, 111: 1011-1018. 10.1111/j.1600-0463.2003.apm1111103.x.CrossRefPubMed
81.
Saad RS, Jasnosz KM, Tung MY, Silverman JF: Endoglin [CD105] expression in endometrial carcinoma. Int J Gynecol Pathol. 2003, 22: 248-253. 10.1097/01.PGP.0000070852.25718.37.CrossRefPubMed
82.
Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors [FLT-1, KDR] and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001, 159: 223-235.PubMedCentralCrossRefPubMed
83.
Adam M, Schmidt D, Wardelmann E, Wernert N, Albers P: Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol. 2003, 44: 329-336. 10.1016/S0302-2838(03)00262-8.CrossRefPubMed
84.
Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 2001, 7: 3410-3415.PubMed
85.
Yagasaki H, Kawata N, Takimoto Y, Nemoto N: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol. 2003, 10: 220-227.CrossRefPubMed
Metadata
Title
Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
Authors
Ester Fonsatti
Michele Maio
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-18

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Commentary

Materializing research promises: opportunities, priorities and conflicts in translational medicine

Review

CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera

Research

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

Research

CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects

Commentary

Granzyme B; the chalk-mark of a cytotoxic lymphocyte

Commentary

Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits